Cappella starts coronary artery stent study
The study will assess the benefits of Sideguard stent as primary intervention, for managing bifurcation related coronary artery disease. The Sideguard stent is designed to preserve the sidebranch
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.